Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Fecal Microbiota Transplantation (FMT) to Slow Biological Aging (LONGEVIBIOME)

30 de octubre de 2026 actualizado por: Human Biome S.A.

A Randomized, Double-blind, Placebo-controlled Research Study Evaluating the Efficacy and Safety of Multi-dose Fecal Microbiota Transplantation (FMT) in Capsule Form as an Intervention to Slow Down the Rate of Biological Aging.

The goal of this clinical trial is to evaluate if multi-dose fecal microbiota transplantation (FMT) capsules can safely and effectively slow down biological aging and reduce chronic low-grade inflammation in adults aged 45 to 80 with metabolic neglect.

The main questions it aims to answer are:

  • Can oral FMT capsules significantly slow the biological pace of aging as measured by the DunedinPACE epigenetic clock?
  • Can FMT successfully reduce chronic systemic inflammation (measured by markers such as suPAR, IL-6, and hs-CRP)?

Researchers will compare participants receiving the active product to those receiving a matching placebo to see if the microbiome intervention improves metabolic health and cognitive function via the gut-brain axis.

Participants will:

  • Undergo a short-term preparation phase involving targeted antibiotics and standard bowel cleansing.
  • Receive an 2 initial induction doses of active product (or placebo) followed by 5 regular booster cycles administered approximately every 4 weeks.
  • Attend periodic clinical visits for physical examinations, blood draws, stool sample collection (at home), and cognitive testing using the CANTAB platform and MoCA scale.
  • Maintain a participant diary to record adverse events (AE), product administration, stool sample collection, and dietary habits.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

68

Fase

  • No aplica

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

45 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Voluntary written informed consent signed prior to any study-related procedures.
  • Age between 45 and 80 years (inclusive) at the time of screening.
  • Classified as "metabolically neglected" with documented pre-disease conditions or regulated early-stage chronic disorders.
  • Accelerated biological aging rate 1.1, OR between 1.05 and 1.099 combined with chronic low-grade inflammation (inflammaging).
  • Preserved cognitive function with a Montreal Cognitive Assessment (MoCA) score between 24 and 30 points.
  • Physical ability to perform computerized cognitive tests on a touch-screen tablet.
  • Commitment to maintaining stable dietary and physical activity habits throughout the study period.
  • Possession of a home freezer and ability to strictly comply with cold-chain storage logistics for investigational products and stool samples.
  • Demonstrated ability to swallow large capsules.
  • Adequate baseline laboratory parameters (such as blood counts and kidney function).
  • For women of childbearing potential: agreement to use a highly effective method of contraception throughout the study and for 30 days post-intervention.
  • Readiness to ensure presence at the registered home address to receive scheduled frozen-chain courier shipments.

Exclusion Criteria:

  • Systemic antibiotic therapy within 12 weeks prior to baseline.
  • Supplementation with any commercial pre- or probiotics within 4 weeks prior to baseline.
  • Diagnosed malignancy within the past 5 years (except fully cured basal cell carcinoma or cervical cancer in situ).
  • Participation in any other clinical study or trial within 30 days prior to consent or during this study.
  • Pregnancy, breastfeeding, or planning a pregnancy during the study and for 30 days post-intervention.
  • Known hypersensitivity, intolerance, or allergy to any component of the investigational product (MBiotix HBI Caps), placebo, preparation antibiotics (Neomycin, Metronidazole), antibiotic placebo, or bowel cleansing solution (macrogols).
  • Pre-existing hearing loss, chronic tinnitus, or diagnosed vestibular disorder. History of or active peripheral neuropathy of any etiology.
  • Myasthenia gravis or other neuromuscular transmission disorders.
  • Concurrent, ongoing use of loop diuretics, other aminoglycoside antibiotics, or known nephrotoxic drugs.
  • Severe, unstable, or uncontrolled comorbidities, including NYHA Class III/IV heart failure, unstable angina, or myocardial infarction within the past 6 months.
  • Severe hepatic impairment (Child-Pugh Class C) or severe renal impairment (eGFR < 30 mL/min/1.73 m²).
  • Active, severe psychiatric disorders (e.g., severe depression with active suicidal ideation, psychotic disorders, unstable bipolar disorder).

Diagnosis of progressive neurodegenerative diseases (Parkinson's, Alzheimer's) or moderate-to-advanced dementia.

  • Active, clinically significant inflammatory bowel disease (Crohn's disease, ulcerative colitis) or other severe gastrointestinal disorders.
  • Evidence of gastrointestinal mucosal damage (ulceration, perforation, bleeding) within 7 days prior to the first product dose.
  • Clinically significant immunosuppression, including chronic systemic corticosteroids, HIV infection with a CD4+ cell count < 200/µl, history of solid organ or hematopoietic stem cell transplantation.
  • Active infection requiring antibiotics during the induction phase or anticipated antibiotic use during the first 7 days post-induction.
  • Prior fecal microbiota transplantation (FMT) treatment for indications other than recurrent C. difficile infection.
  • Significant dysphagia precluding safe capsule ingestion.
  • Inadequate baseline laboratory parameters (such as blood counts and kidney function).
  • Any medical condition or circumstance judged by the Principal Investigator to compromise participant safety or protocol adherence.
  • Anticipated inability to comply with study procedures, such as missing scheduled follow-up visits, lacking reliable home freezer storage, or having a lifestyle/occupation that prevents proper cold-chain product handling or consistent attendance.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: MBiotix HBI Caps

MBiotix HBI Caps (FMT capsules) + Preparation antibiotics (Neomycin and Metronidazole) + Standard bowel cleansing (Macrogols). Participants receive targeted preparation antibiotics followed by bowel cleansing, and then a multi-dose regimen of fecal microbiota transplantation (FMT) capsules (MBiotix HBI Caps) in an initial induction phase and subsequent booster cycles.

Fecal microbiota transplantation (FMT) capsules administered in an initial induction phase followed by subsequent booster cycles. Frozen oral capsules containing full-spectrum human gut microbiota given as an initial induction (comprising a single dose on Day 7 and split daily doses on Days 9-14) following preparation, followed by intermittent 6-day booster cycles administered approximately every 4 weeks.

Comparador de placebos: Placebo

Placebo Capsules (matching MBiotix HBI Caps) + Antibiotics Placebo (matching two active antibiotics) + Standard bowel cleansing (Macrogols). Participants receive matching placebo treatments for both the preparation antibiotics and the oral capsules (MBiotix HBI placebo), along with the same standard bowel cleansing and multi-dose schedule (an initial induction phase and subsequent booster cycles).

Placebo Capsules (Comparator): Frozen oral capsules identical in appearance, packaging, and dosing schedule to the active product, containing pharmacologically inert substances. Administered as an initial induction phase (single dose on Day 7 and split daily doses on Days 9-14) following preparation, followed by intermittent 6-day booster cycles administered approximately every 4 weeks

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants Achieving Clinical and Biological Response (Responder Rate)
Periodo de tiempo: Baseline, Week 13, and Week 26

The primary outcome is the proportion of participants categorized as "Responders" following multi-dose fecal microbiota transplantation (MBiotix HBI Caps) compared to placebo. A participant is classified as a Responder if they demonstrate objective physiological improvement from Baseline to Week 13 and/or Week 26, defined as meeting at least one of the following two pre-specified criteria:

  • Epigenetic Deceleration: A reduction of at least 5% from baseline in the DunedinPACE biological pace-of-aging algorithm.
  • Attenuation of Inflammaging: A reduction of at least 25% from baseline in at least one circulating systemic inflammatory marker from the predefined panel (provided the marker was significantly elevated at baseline per study inclusion criteria).

Results will be reported as the percentage of participants in each treatment arm meeting this composite response definition.

Baseline, Week 13, and Week 26

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

1 de diciembre de 2027

Finalización del estudio (Estimado)

1 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

23 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

30 de octubre de 2026

Publicado por primera vez (Actual)

3 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

30 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 13/HBI/2026

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .